Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts give Kailera Therapeutics a “Moderate Buy” consensus, with five buy ratings, one strong-buy, one hold and one sell. The average 12-month price target is $42.75.
• KLRA opened at $12.15, compared with a 52-week range of $9.76 to $28.23, while the company reported a quarterly loss of $1.09 per share—$0.35 worse than analyst expectations.
• Several institutional investors recently initiated positions, including Atlas Venture Life Science Advisors, Wellington Management, Frazier Life Sciences Management and State Street, as Kailera continues developing obesity and metabolic-disease treatments.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $42.75.

Separately, Weiss Ratings upgraded shares of Kailera Therapeutics from a "sell (d-)" rating to a "sell (d)" rating in a report on Wednesday, October 21st.

Kailera Therapeutics Price Performance

KLRA stock opened at $12.15 on Tuesday. The company has a market cap of $1.58 billion and a P/E ratio of -0.00. Kailera Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $28.23. The business's fifty day moving average price is $13.19.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, analysts predict that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kailera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KLRA. Frazier Life Sciences Management L.P. bought a new stake in shares of Kailera Therapeutics in the 2nd quarter worth about $24,233,000. State Street Corp purchased a new stake in Kailera Therapeutics in the 2nd quarter valued at about $19,126,000. Atlas Venture Life Science Advisors LLC purchased a new position in shares of Kailera Therapeutics during the second quarter valued at $113,923,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the 2nd quarter worth $64,308,000. Finally, Mirador Capital Partners LP purchased a new position in Kailera Therapeutics in the third quarter worth $666,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company's activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics' specific product candidates, operating geographies and leadership is limited.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.